EUCTR2004-004072-37-IT
进行中（未招募）
不适用
CETUXIMAB AND FOLFIRI AS FIRST-LINE TREATMENT OF LOCALLY ADVANCED AND METASTATIC GASTRIC CANCER
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI0 个研究点目标入组 25 人2006年4月21日
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- 未指定
- 发起方
- AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
- 入组人数
- 25
- 状态
- 进行中（未招募）
- 最后更新
- 14年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range
排除标准
- 未提供
结局指标
主要结局
未指定
相似试验
已完成
2 期
Conversion therapy of Cetuximab plus FOLFIRI followed by Bevacizumab plus mFOLFOX6 in patients with liver metastatic colorectal cancerJPRN-UMIN000004694agoya Surgical Oncology Group50
进行中（未招募）
1 期
Phase II study on the use of the FOLFIRI + Cetuximab association in the first-line treatment of patients with advanced colorectal carcinoma with wild type RAS and FcYRIIIA-V / Vadvanced colorectal carcinoma with wild type RAS and FcyRIIIA-V / VTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-003778-29-ITIstituto Nazionale Tumori G. Pascale34
招募中
2 期
PhaseII study of Combination FOLFIRI with Cetuximab in patients with advanced/metastatic colorectal cancer previously received oxaliplatin-based chemoterapy.Colorectal CancerJPRN-UMIN000007372Kurume University School of medicine, Department of Surgery30
进行中（未招募）
不适用
First line treatment with Rituximab asociated to CVP plus Interferon in Follicular Lymphoma. Phase II study.Asociación de Rituximab al esquema CVP + Interferón en el tratamiento de primera línea del linfoma folicular - R-CVP-IFEUCTR2005-004761-42-ESFundacion Leucemia y Linfoma
进行中（未招募）
1 期
PHASE II STUDY OF CETUXIMAB FOR THE TREATMENT OF REFRACTORY OR RELAPSED MULTIPLE MYELOMA EMMA-1 (ERBITUX FOR MULTIPLE MYELOMA) - EMMA-1Relapsed or refractory multiple myelomaEUCTR2005-005612-24-DEniversity of Cologne